<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

Benralizumab Noninferior to Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis

Default sub title

minute read

Written by HealthDay on March 8, 2024

For patients with eosinophilic granulomatosis with polyangiitis (EGPA) receiving standard care, benralizumab is noninferior to mepolizumab, according to a study published in the March 7 issue of the New England Journal of Medicine.

Topics: Press Coverage

Related Stories